BioVendor Group introduces the innovative test for the detection of microsatellite instability leverages state-of-the-art NGS technology.
BioVendor Group introduces its latest product – fastGEN MSI Kit. This innovative test for the detection of microsatellite instability (MSI) leverages state-of-the-art next-generation sequencing (NGS) technology, and delivers unprecedented speed, precision, and sensitivity to the field of molecular diagnostics.
Microsatellite Instability: A Key Biomarker for Diagnosis and Personalized Treatment
MSI is a functional manifestation of defective DNA repair mechanisms, particularly mismatch repair (MMR), leading to changes in the length of DNA microsatellite sequences. Microsatellites, short repetitive sequences of nucleotides, play a crucial role in maintaining genetic stability. When disrupted, they can lead to severe diseases, including various types of cancer.
MSI most commonly occurs in colorectal and endometrial cancers and is also a hallmark of hereditary Lynch syndrome. As such, MSI serves as a critical biomarker that helps physicians diagnose, predict disease progression, and select optimal treatment. Patients with tumours exhibiting high microsatellite instability (MSI-H) show a better response to immunotherapy, such as PD-1/PD-L1 inhibitors.
MSI Detection with NGS Technology: Speed, Precision, and Sensitivity at a New Level
fastGEN MSI Kit is a cutting-edge test based on next-generation sequencing (NGS) technology, offering significantly enhanced speed, precision, and sensitivity compared to traditional methods. NGS enables the detection of even subtle DNA changes and allows the analysis of a wide range of microsatellite sequences.
This broad-spectrum approach is crucial for reliably detection of MSI across various tumour types. The fastGEN MSI Kit covers a wide range of MSI loci, providing a comprehensive view of the tumour’s molecular profile. This information is essential for the selection of targeted therapy and immunotherapy.
Additionally, fastGEN MSI Kit is designed to work effectively with low-quality samples. The technology does not require high DNA concentrations, making it ideal for FFPE samples and those with a low tumour cell content. This advanced approach ensures high reliability of results, even for challenging sample types.
Seamless Integration into Laboratory Processes
The simplicity of fastGEN technology allows for easy implementation of this test into routine laboratory workflows without requiring additional specialized equipment. Its straightforward and efficient workflow and the ability to process multiple samples simultaneously save time and analysis costs.
fastGEN MSI Kit is also compatible with other fastGEN tests, further expanding diagnostic and personalized treatment possibilities.
Fast and Accurate Data Analysis with GENOVESA Software
To enhance data analysis and simplify interpretation of results, fastGEN MSI Kit is tightly integrated with our bioinformatics software GENOVESA. This software ensures quick, efficient data processing and precise result interpretation.
fastGEN MSI: The New Standard in MSI Detection
fastGEN MSI Kit represents a state-of-the-art solution for MSI detection, combining the speed, accuracy, and comprehensiveness of NGS with the advantages of personalized medicine. The fastGEN technology transforms MSI detection from a diagnostic tool into a vital component of the tumour’s molecular profile, significantly contributing to optimized cancer diagnostics and treatment.